Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 2/20 | 0.49 |
| ▸ | CDK2 | P24941 | 2/20 | 0.49 |
| ▸ | CDK9 | P50750 | 2/20 | 0.49 |
| ▸ | CCND3 | P30281 | 2/20 | 0.49 |
| ▸ | CCNK | O75909 | 1/20 | 0.49 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.47 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ABL1 | P00519 | 2/20 | 0.46 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | LCK | P06239 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5997417 | 0.86 | MAPK14 (0.58) | CDK2CDK9CCNT1ABL1EPHX2 | |
| SCHEMBL5996199 | 0.84 | SRC (0.54) | CCNA2CDK2LCKMAPK14 | |
| SCHEMBL5999140 | 0.81 | MEN1 (0.53) | CCNA2CDK2CDK9CCND3CCNK | |
| SCHEMBL5444021 | 0.79 | MEN1 (0.50) | CCNA2CDK2CDK9CCND3CCNK | |
| SCHEMBL5995904 | 0.78 | MAPT (0.47) | CCNA2CDK2CDK9CCND3CCNK | |
| SCHEMBL5995627 | 0.78 | MAPT (0.51) | CCNA2CDK2CDK9CCND3CCNK | |
| SCHEMBL5997968 | 0.76 | MAPK14 (0.74) | CCNA2CDK2CDK9CDK6CCNT1 | |
| SCHEMBL15524783 | 0.73 | MEN1 (0.51) | CCNA2CDK2CDK9CCND3CCNK | |
| SCHEMBL5997421 | 0.72 | SRC (0.57) | ABL1EPHX2NPSR1LCKMAPK14 | |
| SCHEMBL29188760 | 0.72 | KMT2A (0.70) | MEN1KMT2ASMN1; SMN2ABL1RIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060247250-A1 | Pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247250-A1 | Pyrimidine inhibitors of kinases | DTYMK, SRC, DCK | CCNA2 505/4885CDK2 14/4885CDK9 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.